# Mestag Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mestag-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, UK
- Website: www.mestagtx.com
- Total disclosed funding: $41M
- Latest round: Seed (Jul 16, 2021)
- Investors on record: 5

## About

Founded in 2020 by co-founders Susan Hill and Mark Coles and based in Cambridge, UK, Mestag Therapeutics Limited is a developer of a fibroblast-immune cell for the treatment of cancer and inflammatory disease. In August 2024, Mestag Therapeutics Limited raised GBP 1.5 million in grant funding from investor Innovate UK.


Mestag’s pipeline includes MST-0300 and M402, both designed to target specific immune systems. MST-0300 is a bispecific antibody that enhances immune responses in solid tumours by activating fibroblast biology. This approach involves the conditional agonization of the lymphotoxin beta receptor in tumours, promoting the formation of tertiary lymphoid structures (TLS). M402 is another antibody in development, targeting a novel stromal checkpoint to modulate immune responses in inflammatory diseases. By enhancing the function of specific immune checkpoints to mitigate overactive immune responses in inflammatory conditions.


The company aims to use August 2024 funding to further develop its MST-0300 antibody.

## Funding rounds

- Seed, Jul 16, 2021, $30M — SV Health Investors, Johnson & Johnson Innovation, Forbion, GV, Northpond Ventures
- Seed, Apr 20, 2021, $11M — SV Health Investors, Johnson & Johnson Innovation

## Investors

- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Seed
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Seed
- Forbion (https://capitalatlas.ai/funds/forbion) — Seed
- GV (https://capitalatlas.ai/funds/gv) — Seed
- Northpond Ventures (https://capitalatlas.ai/funds/northpond-ventures) — Seed